Global Immunofluorescence Assay Market Size (2024 - 2029)

The immunofluorescence assay market is anticipated to experience growth due to several factors, including the increasing incidence of diseases such as cancer and infectious diseases, which drive demand for diagnostic tools. The market's expansion is further supported by research and development activities, particularly in response to the COVID-19 pandemic, where immunofluorescence assays have shown effectiveness in detecting infections. Initiatives by market players to enhance diagnostic capabilities also contribute to market growth. However, the market faces challenges from the rising popularity of alternative diagnostic procedures.

Market Size of Global Immunofluorescence Assay Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Immunofluorescence Assay Market Analysis
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 5.80 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Global Immunofluorescence Assay Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Immunofluorescence Assay Market Analysis

The Immunofluorescence Assay market studied was projected to grow with a CAGR of 5.8% over the forecast period.

The studied market was impacted by the pandemic. The SARS-CoV-2 outbreak emerged as a potential opportunity for the market's growth. Several research organizations and biopharmaceutical companies are evaluating immunofluorescence assay to develop it as an effective diagnostic tool. The article 'A Novel Immunofluorescence Assay for the rapid serological detection of SARS-CoV-2 infection' published in April 2021, mentions the design of a cell-based fluorescent serology assay to detect SARS-CoV-2 infection. The assay is based on the capture of IgG antibodies in the serum of COVID-19-positive patients using cells exogenously expressing SARS-COV-2 spike and their subsequent fluorescent detection. Such novel immunofluorescent assays implemented to detect COVID-19 infections are expected to impact the growth of the market studied. Also, the article titled 'Rapid Lateral flow immunoassay for the fluorescence detection of SARS-CoV-2 RNA' published in December 2020 mentioned that amplification-free nucleic acid immunoassay, implemented on a lateral flow strip for the fluorescence detection of SARS-CoV-2, achieved sensitivities of 100% and specificities of 99% for both types of throat and sputum samples of COVID-19. The article titled 'Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France' published in May 2020 mentioned that the immunofluorescence assay is useful for monitoring SARS-CoV-2 exposure at the individual and population levels. The effectiveness of these assays for detecting COVID-19 infection is expected to impact the growth of the market studied. Thus, the market was adversely impacted during the initial phase of the pandemic however, its advantages to diagnose COVID are expected to increase its growth during the upcoming period.

The major factor attributing to the growth of the market is the increase in the incidence of disease. Cancer is a major chronic disease in regions such as the Americas, Asia, and Europe. As further research and development activities are being conducted in the area with huge funding from the government, the market studied is expected to grow significantly over time. For instance, as per the Joint Research Commission's report of European Commission released in July 2020, it was estimated that in 2020 about 2.7 million (excluding non-melanoma cancer) new cancer cases would be diagnosed in the European Union, and breast cancer will be the most prevalent form of cancer with about 355,000 new cases in 2020. These conditions of chronic kidney disorders increase the demand for immunofluorescence assay. The American Cancer Society's estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2020 include about 42,810 new cases (30,170 in men and 12,640 in women) diagnosed. According to the study published in Clinical Infectious Diseases, titled 'Re-emergence of Invasive Pneumococcal Disease (IPD) in Germany during the Spring and Summer of 2021' in February 2022, in April 2021, IPD levels in children aged 0 to 4 years old began to rebound to baseline levels. By June 2021, they had surpassed them (a 9 percent increase over the average monthly values for 2015-2019). IPD cases increased beyond baseline values in children 5 to 14, adults 15-34, and people 80 years and older beginning in July 2021, with increases, also beginning in Spring 2021. Such prevalence of infectious diseases is expected to drive the growth of the market studied.

Similarly, initiatives by market players are another factor in market growth. In September 2022, in order to enable subcellular spatial multi-omics measurement with the simultaneous detection of RNA and proteins during a typical MERFISH experiment, Vizgen introduced the MERSCOPE Protein Co-detection Kit. With its oligo conjugated antibodies, the MERSCOPE Protein Stain Reagent Kit enhances the detection of primary antibodies that are directed at proteins and provides high-quality protein staining that is comparable to protein immunofluorescence staining. Thus, the abovementioned factors are expected to increase the market growth.

However, the gaining popularity of the alternative procedures is the major drawback of the market growth

Immunofluorescence Assay Industry Segmentation

As per the scope of the report, immunofluorescence is the specific antigen and antibody reaction where the antibodies are labeled with a fluorescent dye, and the antigen-antibody complex is visualized using a fluorescent microscope. This immunochemical technique allows the detection and localization of a wide variety of antigens in different types of tissues of various cell preparations. The immunofluorescence assay market is segmented by product (reagents and kits, instruments, consumables & accessories), type (indirect immunofluorescence, and direct immunofluorescence), application (cancer, infectious diseases, autoimmune diseases, and others), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across the major regions globally. The report offers the values (USD million) for the above segments.

By Product
Reagents and Kits
Instruments
Consumables & Accessories
By Type
Indirect Immunofluorescence
Direct Immunofluorescence
By Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Immunofluorescence Assay Market Size Summary

The Immunofluorescence Assay market is poised for significant growth, driven by the increasing incidence of chronic diseases such as cancer and the rising prevalence of infectious diseases. The market experienced initial setbacks due to the pandemic; however, the emergence of SARS-CoV-2 presented opportunities for growth as research organizations and biopharmaceutical companies explored immunofluorescence assays for effective COVID-19 diagnostics. The development of novel assays for rapid serological detection and the monitoring of SARS-CoV-2 exposure has been pivotal in shaping market dynamics. Additionally, the market is bolstered by advancements in diagnostic technologies and the introduction of innovative products by key players, which enhance the detection capabilities of immunofluorescence assays.

North America is expected to dominate the Immunofluorescence Assay market, supported by a robust healthcare infrastructure, a high prevalence of diseases, and the presence of major industry players. The region's market growth is further fueled by the increasing demand for effective diagnostic solutions and collaborative initiatives aimed at advancing personalized medicine. The competitive landscape is characterized by the presence of several leading companies, including Thermo Fisher, Bio-Rad Laboratories, and PerkinElmer Inc., which are actively involved in strategic collaborations and acquisitions to strengthen their market positions. Despite the challenges posed by alternative procedures, the market is anticipated to witness substantial growth, driven by the ongoing advancements in diagnostic technologies and the increasing adoption of immunofluorescence assays across various applications.

Explore More

Global Immunofluorescence Assay Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Incidence of Cancer and Other Infectious Diseases

      2. 1.2.2 Growing Investments By Government and Non-government Organizations

    3. 1.3 Market Restraints

      1. 1.3.1 Upsurge of Alternative Tests Which are More Effective

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Product

      1. 2.1.1 Reagents and Kits

      2. 2.1.2 Instruments

      3. 2.1.3 Consumables & Accessories

    2. 2.2 By Type

      1. 2.2.1 Indirect Immunofluorescence

      2. 2.2.2 Direct Immunofluorescence

    3. 2.3 By Application

      1. 2.3.1 Cancer

      2. 2.3.2 Infectious Diseases

      3. 2.3.3 Autoimmune Diseases

      4. 2.3.4 Others

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Immunofluorescence Assay Market Size FAQs

The Global Immunofluorescence Assay Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)

Thermo Fisher, Bio-Rad Laboratories, Inc., Abcam, PerkinElmer Inc. and Werfen are the major companies operating in the Global Immunofluorescence Assay Market.

Immunofluorescence Assay Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)